Phase 2 N=80 Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
Pulmonary Arterial Hypertension · Right Heart Failure
Primary: Change in Six-minute Walk Distance — -17.0; 4.7 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=225 Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
Diabetic Retinopathy
Primary: Proportion of Participants Who Improved by ≥ 2 Steps From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Scores — 12.187; 12.263; 13.311 estimated improvement…
Phase 2 N=62 Vitamin D for Sickle-cell Respiratory Complications
Sickle Cell Disease · Vitamin D Deficiency · Acute Chest Syndrome
Primary: Mean Annual Rate of Respiratory Events — 3.91; 4.34; 3.34; 4.28 events per year
Phase 3 N=3,548 A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
SARS-CoV-2
Primary: Part 1: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain at Day 29 — 537.7; 302.8 AU/mL
Phase 3 N=231 Eptinezumab in Participants With Episodic Cluster Headache
Cluster Headache, Episodic
Primary: Change From Baseline in the Number of Weekly Cluster Headache (CH) Attacks, Averaged Over Weeks 1-2 — -4.0; -4.6 Number of Weekly Attacks — p=0.5048
N/A N=69 Blood Flow Restriction Training for The Shoulder
Healthy
Primary: Determine if BFR Changes UE Lean Muscle Mass in the General Population — -17; 175; 96; 278 g
Phase 3 N=109 A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Pulmonary Tuberculosis
Primary: Proportion of Treatment Failure (Unfavorable Outcome), Defined as Bacteriologic Failure or Relapse or Clinical Failure (Derived) Through Follow-up Until 6 Months After…
N/A N=4 A Feasibility Open Trial of App-Enhanced Brief CBT for Suicidal Inpatients
Suicidal and Self-injurious Behavior
Primary: Client Satisfaction at Discharge — 29.00 score on a scale
N/A N=31 Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase
Peri-Implantitis
Primary: Change in Probing Depth (PD) — -0.73; -1.36 mm
N/A N=98 SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter
Glaucoma
Primary: Visual Field Performance Metric #1 - Mean Deviation — -7.17; -6.88 decibels — p=0.297
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 3 N=957 MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
Glabellar Lines · Lateral Canthal Lines
Primary: Number of Participants Who Experienced Any Adverse Event (AE) — 39; 39; 80; 89 Participants
N/A N=264 Veteran Peer Coaches Optimizing and Advancing Cardiac Health
Cardiovascular Disease (CVD) · Hypertension · Hyperlipemia
Primary: Change in Systolic Blood Pressure (SBP) — -3.32; -0.40 mm Hg — p=0.05
N/A N=257 Randomized Control Trial on Trauma Focused CBT in Zambia
Post Traumatic Stress Disorder · Depression · Risk Behaviors
Primary: Post Traumatic Stress Disorder- Reaction Index (RI) — 1.75; 1.88; 1.38; 0.34 trauma score
Phase 4 N=31 A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
Psoriasis
Primary: Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥…